发明名称 |
Use Of Detection Of Aspartate Transaminase And Lactate Dehydrogenase In Early Evaluation Of Clinical Efficacy Of Antitumor Intervention Measure |
摘要 |
The present invention relates to a method for early evaluation of clinical efficacy of antitumor intervention measure, comprising evaluating the efficacy of the antitumor intervention measure by assaying whether the content of a tumor-damaging biomarker(s) in the blood of a patient having tumor rises as compared to the baseline level before treatment within a time window after the patients receives at least one antitumor intervention measure. In preferable embodiments, the tumor-damaging biomarker(s) is selected from a group consisting of Alanine Aminotransferase (ALT), Aspartate Transaminase (AST), Lactate Dehydrogenase (LDH); said tumor is multiple myeloma; said antitumor intervention measure is the administration of CPT alone or the administration of CPT in combination with thalidomide. |
申请公布号 |
US2014206025(A1) |
申请公布日期 |
2014.07.24 |
申请号 |
US201114240311 |
申请日期 |
2011.08.30 |
申请人 |
Yang Shifang;Cui Junsheng;Wei Peng;Zheng Xiangjun;Zhu Bing |
发明人 |
Yang Shifang;Cui Junsheng;Wei Peng;Zheng Xiangjun;Zhu Bing |
分类号 |
G01N33/50 |
主分类号 |
G01N33/50 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for early evaluation of clinical efficacy of an antitumor intervention measure, comprising:
evaluating the efficacy of the antitumor intervention measure by assaying whether the content of a tumor-damaging biomarker(s) in the blood of a patient having tumor rises as compared to the baseline level before treatment within a time window after the patients receives at least one antitumor intervention measure. |
地址 |
Beijing CN |